Triangle Biotechnology, Inc.

Triangle Biotechnology, Inc., a for-profit biotechnology company based in Chapel Hill, North Carolina, is a federal grant recipient developing proprietary nanodroplet sonication reagents and extraction technologies for diagnostic and research applications in microbiology and epigenomics. The company operates exclusively as a prime recipient on NIH and NSF grants; it holds no federal contracts and no position on contract vehicles.

Triangle Biotechnology's recent federal grant footprint centers on two parallel product lines, both anchored to National Institutes of Health funding. The company is the recipient of a one-million-dollar National Institute of Allergy and Infectious Diseases grant awarded July 20, 2026, under CFDA 93.855 (Allergy and Infectious Diseases Research), running through June 30, 2029, to commercialize SnapLyse, a cavitation-enhancing nanodroplet reagent paired with low-power sonication for microbial lysis and DNA extraction from samples with difficult-to-lyse pathogens such as drug-resistant Mycobacterium tuberculosis. The award funds development of a culture-free, targeted next-generation sequencing diagnostic method. In parallel, Triangle received a National Institute of General Medical Sciences grant (award date August 15, 2023, completion June 2025) to develop ChromExtract, a nanodroplet-based sonication reagent for chromatin extraction from formalin-fixed paraffin-embedded tissues, enabling epigenomic profiling and chromatin accessibility analysis. The company also holds a Cooperative Agreement from the NIH Office of the Director under SBIR PA22-176 (award date September 30, 2023, completion June 29, 2025) for culture-free microbial enrichment and antimicrobial resistance characterization. Across all nine awards in the source data spanning 2018 to 2026, Triangle has received combined federal dollars obligated of thirteen million two hundred thousand dollars from five distinct customer agencies — the National Institutes of Health (National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences), the National Science Foundation, and the Centers for Disease Control and Prevention. The company's award activity shows recent acceleration, with one award in 2026 following a gap in 2021–2022 and prior activity concentrated in 2018–2020. All nine awards are prime recipient grants; Triangle carries no subcontract or sub-recipient role in the source footprint.